BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cohen HP, McCabe D. The Importance of Countering Biosimilar Disparagement and Misinformation. BioDrugs 2020;34:407-14. [PMID: 32691270 DOI: 10.1007/s40259-020-00433-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 10.0] [Reference Citation Analysis]
Number Citing Articles
1 Lobo F, Río-Álvarez I. Barriers to Biosimilar Prescribing Incentives in the Context of Clinical Governance in Spain. Pharmaceuticals (Basel) 2021;14:283. [PMID: 33809934 DOI: 10.3390/ph14030283] [Reference Citation Analysis]
2 Kurki P, Barry S, Bourges I, Tsantili P, Wolff-Holz E. Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory Perspective. Drugs 2021;81:1881-96. [PMID: 34596876 DOI: 10.1007/s40265-021-01601-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Gasteiger C, Petrie KJ. Moving forward: Implementing health psychology research to improve patient acceptance of biosimilars. Res Social Adm Pharm 2022:S1551-7411(22)00085-7. [PMID: 35339394 DOI: 10.1016/j.sapharm.2022.03.009] [Reference Citation Analysis]
4 Barbier L, Mbuaki A, Simoens S, Declerck P, Vulto AG, Huys I. Regulatory Information and Guidance on Biosimilars and Their Use Across Europe: A Call for Strengthened One Voice Messaging. Front Med (Lausanne) 2022;9:820755. [PMID: 35355594 DOI: 10.3389/fmed.2022.820755] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Cohen HP, Hachaichi S, Bodenmueller W, Kvien TK, Danese S, Blauvelt A. Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies. BioDrugs 2022. [PMID: 35881304 DOI: 10.1007/s40259-022-00546-6] [Reference Citation Analysis]
6 Vandenplas Y, Simoens S, Van Wilder P, Vulto AG, Huys I. Informing Patients about Biosimilar Medicines: The Role of European Patient Associations. Pharmaceuticals (Basel) 2021;14:117. [PMID: 33557030 DOI: 10.3390/ph14020117] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
7 Barbier L, Simoens S, Vulto AG, Huys I. European Stakeholder Learnings Regarding Biosimilars: Part I-Improving Biosimilar Understanding and Adoption. BioDrugs 2020;34:783-96. [PMID: 33141421 DOI: 10.1007/s40259-020-00452-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 9.0] [Reference Citation Analysis]
8 Kurki P, Kang HN, Ekman N, Knezevic I, Weise M, Wolff-Holz E. Regulatory Evaluation of Biosimilars: Refinement of Principles Based on the Scientific Evidence and Clinical Experience. BioDrugs 2022. [PMID: 35596890 DOI: 10.1007/s40259-022-00533-x] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Kolbe AR, Kearsley A, Merchant L, Temkin E, Patel A, Xu J, Jessup A. Physician Understanding and Willingness to Prescribe Biosimilars: Findings from a US National Survey. BioDrugs 2021;35:363-72. [PMID: 33826078 DOI: 10.1007/s40259-021-00479-6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Price SM, O'Donoghue AC, Rizzo L, Sapru S, Aikin KJ. What influences healthcare providers' prescribing decisions? Results from a national survey. Res Social Adm Pharm 2021;17:1770-9. [PMID: 33558154 DOI: 10.1016/j.sapharm.2021.01.012] [Reference Citation Analysis]
11 Vandenplas Y, Barbier L, Simoens S, Van Wilder P, Vulto AG, Huys I. Perceptions About Biosimilar Medicines Among Belgian Patients in the Ambulatory Care. Front Pharmacol 2021;12:789640. [PMID: 35069205 DOI: 10.3389/fphar.2021.789640] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Oskouei ST, Kusmierczyk AR. Biosimilar Uptake: The Importance of Healthcare Provider Education. Pharmaceut Med 2021;35:215-24. [PMID: 34420201 DOI: 10.1007/s40290-021-00396-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Krstic M, Devaud JC, Marti J, Sadeghipour F. Exploring the Reasons Behind the Substantial Discontinuation Rate Among Patients Taking CT-P13 in a Large Tertiary Hospital in Western Switzerland: A Retrospective Cohort Study Using Routinely Collected Medical Data. Drugs Real World Outcomes 2022. [PMID: 35590047 DOI: 10.1007/s40801-022-00299-2] [Reference Citation Analysis]
14 Kvien TK, Patel K, Strand V. The cost savings of biosimilars can help increase patient access and lift the financial burden of health care systems. Semin Arthritis Rheum 2021;:151939. [PMID: 35027243 DOI: 10.1016/j.semarthrit.2021.11.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]